Edwards must pay a $10 million fine and add an antitrust program, including FTC notice before some future TAVR-AR deals. It did not admit wrongdoing, but the payment and added limits weigh against the company.
The new program means some future TAVR-AR purchases need FTC notice, adding a step to those deals. Edwards did not admit wrongdoing, but the payment and required changes still create costs and constraints.
Follow Edwards Lifesciences Corp. (EW) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EW